Pipeline Analysis
The 114 targets in SanjingBio's pipeline broken down by indication: oncology dominates, with autoimmune and metabolic together under twenty percent. Set against three years of ADC and bispecific clinical progress, where are the non-oncology gaps?
Pipeline Analysis
H1 approvals summarized by target, indication and drug format (mAb / bispecific / ADC), flagging the share whose early discovery was completed by domestic teams.
Technology Trends
Tracing a decade of antibody formats through conjugation sites, linkers, payloads and bridging architectures — and what each shift demanded of early discovery.
Pipeline Analysis
The 114 targets in SanjingBio's pipeline broken down by indication: oncology dominates, with autoimmune and metabolic together under twenty percent. Set against three years of ADC and bispecific clinical progress, where are the non-oncology gaps?
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.